Advertisement
Johnson & Johnson Reaffirms FY22 Outlook; Authorizes Up To $5 Bln Share Buyback
(RTTNews) - Johnson & Johnson (JNJ) On Wednesday reaffirmed its full-year 2022 guidance for earnings in the range of $10.65 to $10.75 per share and adjusted operational sales growth of 6.5 to 7.5 percent.
On average, 17 analysts polled by Thomson Reuters expect the company to report earnings of $10.07 per share on revenue growth of 1.5 percent to $95.14 billion for the year. Analysts' estimates typically exclude special items.
The company also announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock.
The company said repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. Any shares acquired will be available for general corporate purpose.
read more
Johnson & Johnson Lifts FY26 View, Despite Nearly Flat Q2 Profit; Stock Down
Drug major Johnson & Johnson, while reporting slightly lower second-quarter profit despite sales growth, on Wednesday raised again its earnings and sales forecast for fiscal 2026. The company also announced a quarterly dividend. In pre-market activity, the shares were losing around 1.9 percent.
RTTNews
|
58 days ago
Johnson & Johnson Q1 Profit Down, Sales Rise; Lifts FY26 Outlook
Drug major Johnson & Johnson (JNJ), while reporting sharply lower first-quarter profit despite sales growth, on Tuesday lifted fiscal 2026 earnings and sales forecast for fiscal 2026. The company also announced higher quarterly dividend. In pre-market activity, the shares were losing around 1.6 percent.
RTTNews
|
150 days ago
Johnson & Johnson In Deal With Trump Administration To Cut Drug Prices, Get Tariff Exemption
Drug major Johnson & Johnson has announced an agreement with the Trump Administration to lower drug prices, enabling millions of Americans to access medicines at significantly discounted rates. As part of the deal, the company's pharmaceutical products will be exempt from tariffs, though the specific terms remain confidential.
RTTNews
|
245 days ago
Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast
Johnson & Johnson reported Wednesday weak profit in its second quarter on charges, while adjusted earnings beat market estimates on sales growth. The drug major further trimmed its fiscal 2024 adjusted earnings outlook, but lifted operational sales view to mainly reflect the acquisition of Shockwave Medical. In pre-market activity on the NYSE, Johnson & Johnson shares were losing around 0.5...
RTTNews
|
786 days ago
Johnson & Johnson To Acquire Rights To Numab Therapeutics' Clinical-Stage Bispecific Antibody NM26
Johnson & Johnson (JNJ) announced Tuesday it has entered into a definitive agreement with biotechnology company Numab Therapeutics to acquire its wholly-owned subsidiary from Numab's shareholders in an all-cash transaction of approximately $1.25 billion.
RTTNews
|
836 days ago
J&J Seeks EMA Approval For DARZALEX Quadruplet Therapy For Multiple Myeloma
Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), announced Wednesday the submission of a Type II variation application to the European Medicines Agency (EMA).
RTTNews
|
919 days ago
AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial
Swiss biopharmaceutical company AC Immune SA (ACIU) announced Friday that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms.
RTTNews
|
1001 days ago
Integra LifeSciences To Acquire Acclarent For $275 Mln Cash
Medical technology firm Integra LifeSciences Holdings Corp. (IART) announced Wednesday that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company, for $275 million in cash at closing. This is subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones.
RTTNews
|
1003 days ago
